Literature DB >> 17237286

Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.

Aparna V Sarthy1, Susan E Morgan-Lappe, Dorothy Zakula, Lawrence Vernetti, Mark Schurdak, Jeremy C L Packer, Mark G Anderson, Senji Shirasawa, Takehiko Sasazuki, Stephen W Fesik.   

Abstract

To identify cancer-specific targets, we have conducted a synthetic lethal screen using a small interfering RNA (siRNA) library targeting approximately 4,000 individual genes for enhanced killing in the DLD-1 colon carcinoma cell line that expresses an activated copy of the K-Ras oncogene. We found that siRNAs targeting baculoviral inhibitor of apoptosis repeat-containing 5 (survivin) significantly reduced the survival of activated K-Ras-transformed cells compared with its normal isogenic counterpart in which the mutant K-Ras gene had been disrupted (DKS-8). In addition, survivin siRNA induced a transient G(2)-M arrest and marked polyploidy that was associated with increased caspase-3 activation in the activated K-Ras cells. These results indicate that tumors expressing the activated K-Ras oncogene may be particularly sensitive to inhibitors of the survivin protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237286     DOI: 10.1158/1535-7163.MCT-06-0560

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  41 in total

1.  Expanding applications of chemical genetics in signal transduction.

Authors:  Scott M Carlson; Forest M White
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

2.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 3.  Target validation to biomarker development: focus on RNA interference.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 4.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

5.  An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates.

Authors:  Bhavneet Bhinder; Christophe Antczak; Christina N Ramirez; David Shum; Nancy Liu-Sullivan; Constantin Radu; Mark G Frattini; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2012-11-30       Impact factor: 1.738

Review 6.  RAS isoforms and mutations in cancer at a glance.

Authors:  G Aaron Hobbs; Channing J Der; Kent L Rossman
Journal:  J Cell Sci       Date:  2016-03-16       Impact factor: 5.285

7.  Depletion of K-Ras promotes proteasome degradation of survivin.

Authors:  Awet Tecleab; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

8.  PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival.

Authors:  Elizabeth W Bradley; Ming M Ruan; Merry J Oursler
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

9.  MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.

Authors:  Chih-Shia Lee; Liam C Lee; Tina L Yuan; Sirisha Chakka; Christof Fellmann; Scott W Lowe; Natasha J Caplen; Frank McCormick; Ji Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-01       Impact factor: 11.205

10.  Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay.

Authors:  Crystal D Zellefrow; Elizabeth R Sharlow; Michael W Epperly; Celeste E Reese; Tongying Shun; Ana Lira; Joel S Greenberger; John S Lazo
Journal:  Radiat Res       Date:  2012-07-02       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.